Entera Bio Ltd. (ENTX)

NASDAQ: ENTX · USD

$3.10

+0.04 (+1.3%)· Recorded snapshot

Market cap	539.2M
Net income (ttm)	-17M
EPS (ttm)	-$0.35
Shares out	173.9M
Volume	172,118
Beta	1.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -17M
EPS (ttm): -$0.35
Market cap: 539.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-138.9

P25 n/aP50 n/aP75 n/a

ROIC-71.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ENTX indicators

Market & fundamental data

Available fields

179

Groups with data

Currency

USD

Showing 179 of 179 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001638097
Company name	Entera Bio Ltd.
Country	Israel
Country code	US
CUSIP number	M40527109
Earnings date	2026-11-13
Earnings time	amc
Employees	22
Employees change	2
Employees growth	10%
Enterprise value	$528.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2010
Industry	Biotechnology
IPO date	2018-06-28
Is primary listing	Yes
Is SPAC	No
ISIN number	IL0011429839
Last 10-K release date	2026-03-27
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$539.2M
Market cap category	Small-Cap
Next earnings date	2026-11-13
Options	Yes
Price	$3.10
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ENTX
Website	https://enterabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-11.41%
FCF / EV yield	-2.08%
FCF yield	-2.04%
P/B ratio	20.76x
Price / tangible book value	73.96x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-774,227
ROA	-45.98%
ROA (5Y)	-48.78%
ROCE	-82.87%
ROE	-138.92%
ROE (5Y)	-89.77%
ROIC	-71.57%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth	-76.8%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-73,000
Depreciation and amortization	$31,000
EBIT	$-14.4M
EBITDA	$-14.4M
EPS	$-0.35
FCF per share	$-0.06
Financing cash flow	$10.5M
Free cash flow	$-11M
Free cash flow minus SBC	$-13.9M
Investing cash flow	$-73,000
Net cash flow	$-392,000
Net income	$-17M
Operating cash flow minus SBC	$-13.8M
Operating income	$-14.4M
Stock-based compensation	$2.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-7.26
Book value per share	$0.15
Debt / equity	0.06
Interest coverage	-5.3
Long-term assets	$584,000
Long-term liabilities	$10.1M
Net cash (debt)	$10.9M
Net cash / market cap	2.03%
Net cash growth	2.15%
Net debt / equity	-1.5
Piotroski F-Score	1
Property, plant and equipment	$483,000
Shareholders' equity	$7.3M
Tangible book value	$7.3M
Tangible book value per share	$0.15
Total assets	$19.5M
Total cash	$11.3M
Total debt	$425,000
Total liabilities	$12.2M
WACC	12.38%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$18.9M
Current liabilities	$2.1M
Current ratio	8.98
Net working capital	$5.7M
Quick ratio	5.42
Working capital	$16.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-15.33%
Dividend yield	0%
Shareholder yield	-15.33%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.06
1D price change	1.31%
1M price change	14.21%
1M total return	14.21%
1W price change	3.81%
1W total return	3.81%
1Y price change	34.55%
1Y return CAGR	34.58%
1Y total return	34.55%
20-day SMA	$2.78
200-day SMA	$1.89
3M price change	-20.03%
3M total return	-20.03%
3Y price change	361.5%
3Y return CAGR	66.47%
3Y total return	361.5%
50-day SMA	$2.90
50-day SMA vs 200-day SMA	50over200
52-week high	$4.20
52-week high date	2026-07-27
52-week low	$0.91
52-week low date	2026-03-30
5Y price change	-22.4%
5Y return CAGR	-4.95%
5Y total return	-22.4%
6M price change	172.61%
6M total return	172.61%
All-time high	$10.16
All-time high date	2021-03-12
All-time low	$0.47
All-time low date	2022-11-11
Average true range (ATR)	$0.21
Average volume	657.3K
Beta (1Y)	-0.26
Beta (2Y)	0.17
Beta (5Y)	1.41
Change from 52-week high	-26.19%
Change from 52-week low	240.66%
Change from all-time high	-69.14%
Change from all-time low	563.91%
Change from open	1.31%
Day's gap	0%
Dollar volume	$533,566
High price	$3.18
Low price	$3.06
Monthly RSI	64.19
Open price	$3.06
Position in 52-week range	33.33%
Premarket change	-2.94%
Premarket close	$3.06
Premarket price	$2.97
Premarket volume	102
Previous close	$3.06
Price vs 150-day SMA	52.48%
Price vs 20-day SMA	12.65%
Price vs 200-day SMA	65.79%
Price vs 50-day SMA	8.22%
Relative volume	0.26
RSI	61.47
Sharpe ratio	0.71
Sharpe ratio (3Y)	0.92
Sharpe ratio (5Y)	0.32
Sortino ratio	1.68
Sortino ratio (3Y)	1.93
Sortino ratio (5Y)	0.67
Volume	172.1K
Weekly RSI	65.85
YTD price change	61.6%
YTD total return	61.6%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	127.2M
Float percentage	73.11%
Shares change (QoQ)	5.64%
Shares change (YoY)	15.33%
Shares held by insiders	0.88%
Shares held by institutions	13.25%
Shares outstanding	173.9M
Short % of float	1.89%
Short % of shares	1.38%
Short ratio	5.8 days

Deeper analysis on ENTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ENTX report

Is a complete ENTX research report available?

No complete published report is available for Entera Bio Ltd. (ENTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Entera Bio Ltd. (ENTX)

Price

Financial snapshot

Fair-value bridge

Latest news · ENTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ENTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ENTX

Frequently asked questions